Kaken Pharmaceutical Co., Ltd. provided consolidated earnings guidance for the fiscal year ending March 31, 2023. For the period, the company expected net sales of JPY 76,400 million, operating profit of JPY 15,000 million, profit attributable to owners of parent of JPY 12,000 million and basic earnings per share of JPY 317.31.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
3,478 JPY | +0.03% | +2.08% | +3.67% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+3.67% | 861M | |
+21.85% | 546B | |
-4.77% | 359B | |
+16.97% | 323B | |
+5.69% | 290B | |
+13.68% | 234B | |
+3.65% | 198B | |
-11.12% | 194B | |
+8.08% | 167B | |
-3.40% | 157B |
- Stock Market
- Equities
- 4521 Stock
- News Kaken Pharmaceutical Co., Ltd.
- Kaken Pharmaceutical Co., Ltd. Provides Consolidated Earnings Guidance for the Fiscal Year Ending March 31, 2023